

1. A method of modulating cell proliferation comprising contacting a cell with a composition comprising a variant type 2 methionine aminopeptidase ("MetAP2"), which has dominant negative MetAP2 activity and comprises a translation domain.
2. The method of claim 1 wherein the cell is an endothelial cell.
3. The method of claim 2 wherein the endothelial cell is in vitro.
4. The method of claim 1 wherein the composition consists essentially of a variant MetAP2 translation domain.
5. The method of claim 4 wherein the translation domain consists of a sequence identified by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:15.
6. The method of claim 1 wherein the composition consists of an amino acid sequence identified by SEQ ID NO:6 and wherein the amino acid at position 231 of SEQ ID NO:6 is Alanine.
7. The method of claim 6, wherein the composition has a sequence identified by SEQ ID NO:6, 7, 8, or 16.
8. The method of claim 1 wherein the translation domain has a sequence identified by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:15.
9. A method of modulating cell proliferation comprising contacting a cell with a composition comprising an isolated and purified polynucleotide, wherein the polynucleotide encodes a variant MetAP2 that has dominant negative methionine MetAP2 activity and comprises a translation domain.
10. The method of claim 9 wherein the cell is an endothelial cell.
11. The method of claim 9 wherein the polynucleotide is part of a vector and operably linked to a promoter.
12. The method of claim 11, wherein said vector is an adenovirus vector.
13. The method of claim 11, wherein said promoter is a CMV promoter.
14. The method of claim 11 wherein said vector is an adenovirus vector and said promoter is a CMV promoter.
15. The method of claim 9 wherein the variant MetAP2 consists essentially of a sequence identified by SEQ ID NO:6, 7, 8, or 16.
16. The method of claim 9 wherein the variant MetAP2 consists essentially of a translation domain.
17. The method of claim 16 wherein the translation domain has a sequence identified by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:15.

18. The method of claim 9 wherein the polynucleotide has a sequence identified in any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:18.

19. A method of modulating cell proliferation comprising contacting a cell with a composition consisting essentially of a variant type 2 methionine aminopeptidase (MetAP2) translation domain that has dominant negative MetAP2 activity.

20. The method of claim 19 wherein said composition consists of a variant MetAP2 translation domain that has dominant negative MetAP2 activity.